Clinical Trial Update: A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study [Phase 3]

View source ↗

Summary

Long-term extension study of tocilizumab (RoActemra/Actemra) in children with Juvenile Idiopathic Arthritis who completed the core WA19977 study; the trial is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2015-10-02